• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Evaxion A/S

    4/22/26 7:00:08 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EVAX alert in real time by email
    6-K 1 f6k_042126.htm FORM 6-K

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 6-K 

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO SECTION 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of April 2026

    Commission File Number: 001-39950

     

     

     

    Evaxion A/S

    (Exact Name of Registrant as Specified in Its Charter) 

     

    Dr. Neergaards Vej 5f

    DK-2970 Hoersholm

    Denmark

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒            Form 40-F ☐

     

     

    INCORPORATION BY REFERENCE

    This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s (the “Company”) registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

     

     

    Resolutions passed at the Annual General Meeting

    On April 16, 2026, Evaxion A/S (the “Company”) held its Annual General Meeting and 104,894,401 ordinary shares of the Company representing in total 25,15 % of the ordinary shares outstanding as of the date of the Annual General Meeting, were voted at the meeting. The final results of each of the agenda items submitted to a vote of the shareholders are as follows:

    Agenda Item 1: Election of the chairman of the meeting

    Attorney-at-law Lars Lüthjohan was elected as chairman of the meeting.

     

    Agenda Item 2: The board of directors' report on activities of the Company in the past year

    The General Meeting took note of the report of the board of directors on the activities of the Company in the past year.

     

    Agenda Item 3: Presentation of the audited annual report for adoption

    The General Meeting approved the Company’s audited annual report for the financial year 2025.

     

    Agenda Item 4: Resolution on the allocation of profit or coverage of loss, cf. the adopted annual report

    The General Meeting approved that the loss related to the financial year 2025 be transferred to the next financial year.

     

    Agenda Item 5: Election of members to the board of directors

     

    Questions were asked and answered to the General Meeting’s satisfaction.


    Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner and Roberto Prego Pineda were re-elected as members of the board of directors.

     

    Jens Bitsch-Nørhave was elected as a new board member.

     

     

    Agenda Item 6: Election of auditor

     

    EY Godkendt Revisionspartnerselskab was re-elected as the Company’s auditor in accordance with the recommendation from the board of directors.

     

    Agenda Item 7: Any motion from the board of directors and/or the shareholders

    7a – Proposal from the board of directors – proposal to authorize the board of directors to issue warrants

    The board of directors proposed to amend the articles of association by increasing the current authorization in article 2.5 of the articles of association to issue warrants to members of the Company's board of directors and executive management as well as key-employees of the Company or its subsidiaries to nominal DKK 11,900,000. The board of directors specifically proposed that the existing authorization in article 2.5 was amended as follows:

    “The board of directors is until 15 April 2029 authorized at one or more times to issue warrants to members of the company's board of directors and executive management as well as key employees of the company or its subsidiaries entitling the holder to subscribe for shares for a total of up to nominal value of DKK 11,900,000 without pre-emptive subscription rights for the company's shareholders. The exercise price for the warrants issued according to this authorization shall be determined by the board of directors at market price. The board of directors shall determine the terms for the warrants issued and the distribution hereof.

    At the same time, the board of directors is authorized until 15 April 2029 at one or more times to increase the company's share capital with up to nominal value of DKK 11,900,000 without pre-emptive rights for the company's shareholders by cash payment in order to implement the capital increase related to exercise of warrants. In accordance with this clause the board of directors may increase share capital with a minimum nominal value of DKK 0.25 and a maximum nominal value of DKK 11,900,000.

    The shares issued based on exercise of warrants shall be non-negotiable instruments issued in the name of the holder and registered in the name of the holder in the company's register of shareholders. The shares shall be subject to the same restrictions on transferability as the existing shares of the company and no shareholder shall be obliged to have the shares redeemed fully or partly. No partial payment is allowed. The shares shall be with the same rights as the existing share capital and shall not belong to a specific share class. The shares shall give rights to dividends and other rights in the company from the time of registration of the capital increase with the Danish Business Authority.”

    The General Meeting adopted the proposal to amend the existing authorization in article 2.5 of the articles of association with the required majority.

     

     

    7b - Proposal from the board of directors – proposal to authorize the board of directors to obtain loans against issuance of convertible loan notes

    The board of directors proposed to replace the lapsed authorization in article 3.3 of the articles of association with a new authorization to obtain loans against issuance of convertible loan note which gives the right to subscribe for shares for a total of up to nominal value of DKK 73,500,000 without pre-emptive subscription rights for the Company's shareholders. The board of directors specifically proposed that an updated authorization in article 3.3 was adopted as follows:

    “The board of directors is until 15 April 2031 authorized at one or more times to obtain loans against issuance of convertible loan notes which give the right to subscribe for shares for a total of up to nominal value of DKK 73,500,000 without pre-emptive subscription rights for the company's shareholders. The conversion shall be carried out at a price that corresponds in aggregate to at least the market price at the time of the decision of the board of directors. Shares shall be considered issued at market price if the shares are issued at +/-10% of the listed price for the company’s shares on a relevant stock exchange in Europe or the USA. The loans shall be paid in cash. The terms and conditions for the convertible loan notes shall be determined by the board of directors.

    As a consequence of the conversion of the convertible loan notes, the board of directors is authorized until 15 April 2031 to increase the share capital by a nominal value of up to DKK 73,500,000 by conversion of the convertible loan notes. The company's shareholders shall not have pre-emptive rights to subscribe for shares issued by conversion of the convertible loan notes. The shares issued based on convertible loan notes shall be non-negotiable instruments issued in the name of the holder and registered in the name of the holder in the company's register of shareholders. The shares shall be subject to the same restrictions on transferability as the existing shares of the company and no shareholder shall be obliged to have the shares redeemed fully or partly. No partial payment is allowed. The shares shall be with the same rights as the existing share capital and shall not belong to a specific share class. The shares shall give rights to dividends and other rights in the company from the time of registration of the capital increase with the Danish Business Authority.”

    The General Meeting adopted the proposal to amend the existing authorization in article 3.3 of the articles of association with the required majority.

     

    Agenda Item 8: Proposal to authorize the chairman of the meeting

     

    The chairman of the General Meeting (with a right of substitution) was with the required majority authorized on behalf of the Company to apply the Danish Business Authority for registration of the resolutions passed by the General Meeting and in this connection to make any such amendments to the documents prepared for such resolutions that may be required for registration with the Danish Business Authority.

     

    Agenda Item 9: Miscellaneous

    Questions were asked and answered to the General Meeting’s satisfaction.

     

    The Company’s Articles of Association were amended as of April 16, 2026, to reflect the above proposals from the Company’s Annual General Meeting and are attached hereto as Exhibit 3.1.

     

     

    Exhibits

    Exhibit    
    No.   Description
         
    3.1   Articles of Association

     

     

     

     

     

     

     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Evaxion A/S
       
    Date: April 22, 2026 By: /s/ Dr. Helen Tatyon-Martin
        Dr. Helen Tayton-Martin
       

    Chief Executive Officer

     

    Get the next $EVAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVAX

    DatePrice TargetRatingAnalyst
    2/19/2026$10.00Buy
    Maxim Group
    4/2/2024$8.00Neutral → Buy
    Ladenburg Thalmann
    2/12/2024$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $EVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 3 filed by new insider Mattsson Andreas Holm

    3/A - Evaxion A/S (0001828253) (Issuer)

    4/10/26 4:20:54 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 3 filed by new insider Soegaard Marianne

    3/A - Evaxion A/S (0001828253) (Issuer)

    4/2/26 4:06:38 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 3 filed by new insider Wegner Lars Aage Staal

    3/A - Evaxion A/S (0001828253) (Issuer)

    4/1/26 8:55:35 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

    New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune responseThe results reinforce that Evaxion's pioneering AI platform, AI-Immunology™ accurately identifies and selects the most relevant vaccine targetsData will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating that AI-Immunology™ identifies and selects the most therapeutically relevant vaccine targets. The

    4/17/26 3:10:00 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New data demonstrates the unique scalability of Evaxion's AI-Immunology™ platform in glioblastoma

    Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastomaUniquely, the platform can identify a novel source of targets to include in glioblastoma cancer vaccines, potentially enhancing their efficacyData will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating the platform's ability to also potentially develop vaccines for glioblastom

    4/17/26 3:00:00 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion concludes Annual General Meeting

    COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual General Meeting today at the company's offices. The 2025 Annual Report was approved and the Board of Directors' proposals passed. Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner and Roberto Prego Pineda were re-elected to the Board of Directors. Jens Bitsch Nørhave was elected to the Board of Directors. Minutes from the meeting can be found on our website. Contact information Evaxion A/S Mads Kronborg Vice President, Investor Relations & Communication +45 53 54 82 96 [email protected] Abo

    4/16/26 11:30:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Evaxion Biotech with a new price target

    Maxim Group initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $10.00

    2/19/26 8:24:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion Biotech upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded Evaxion Biotech from Neutral to Buy and set a new price target of $8.00

    4/2/24 11:31:47 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Evaxion Biotech with a new price target

    H.C. Wainwright initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $14.00

    2/12/24 6:37:53 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    Financials

    Live finance-specific insights

    View All

    Evaxion plans to file 2025 annual report later today

    COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today, due to unforeseen technical issues with external vendors.   The report has been finalized as planned and will be filed and published as soon as possible. The technical issues relate to regulatory filing demands and have nothing to do with the report itself.  As a consequence of the technical delay, the conference call and webcast planned for today will be moved to tomorrow: Friday March 6 at 8.30 E

    3/5/26 8:02:13 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion to announce business update and full year 2025 financial results on March 5, 2026

    COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its full year 2025 financial results on Thursday March 5, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be acces

    3/2/26 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

    Correcting press release issued under same heading: Date in body text corrected to "November 6, 2025" as in headline. COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2025 financial results on Thursday November 6, 2025, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. To join the conference call, listen

    10/31/25 9:05:34 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    Leadership Updates

    Live Leadership Updates

    View All

    Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

    Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than 30 years of experience include leadership roles in the UK and US, from early research through to product approval in cancer immunotherapy, making her the ideal candidate to lead the next stage of execution of Evaxion's strategy Birgitte Rønø, who has served as interim Chief Executive Officer, will continue in her role as Chief Scientific OfficerSeasoned life science executive Jens Bitsch-Norhave will join as observer and advisor to the Board of Directors with the intention of seeking election at the

    10/27/25 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer

    Dr. Rønø has developed Evaxion's pre-clinical and early clinical oncology pipelineNewly-created Chief Scientific Officer role strengthens Evaxion's leadership team COPENHAGEN, Denmark, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has promoted its Senior Director, Immuno-Oncology, Birgitte Rønø, Ph.D, to the newly-created position of Chief Scientific Officer, effective immediately. Lars Wegner, CEO of Evaxion, said: "As Senior Di

    9/21/21 8:34:52 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion Biotech Appoints Lars Holtug to the Board of Directors

    COPENHAGEN, Denmark, May 26, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today its shareholders elected Lars Holtug, a highly experienced financial professional with specific expertise in the healthcare industry, as a member of its Board of Directors. The vote was held at Evaxion's Annual General Meeting on May 25, 2021. Lars Holtug will also chair Evaxion's Audit Committee, taking over from Helen M. Boudreau, who chose not to stand for re-election for personal reasons. Marianne Søgaard, Chairwo

    5/26/21 8:30:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Evaxion Biotech A/S

    SC 13G - Evaxion Biotech A/S (0001828253) (Subject)

    11/14/24 3:29:53 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evaxion Biotech A/S

    SC 13G/A - Evaxion Biotech A/S (0001828253) (Subject)

    11/6/24 4:09:57 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Evaxion Biotech A/S

    SC 13G - Evaxion Biotech A/S (0001828253) (Subject)

    1/23/24 3:29:11 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    SEC Filings

    View All

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    4/22/26 7:00:08 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    4/17/26 3:30:06 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    4/17/26 3:20:06 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care